This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuhn, J. G. Search for Related Content PubMed PubMed Citation Articles by Kuhn, J. G.

Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma

Authors' Affiliations: ¹ University of Texas Health Science Center, San Antonio, Texas; ² University of California at San Francisco, San Francisco, California; ³ Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts; ⁴ University of California at Los Angeles, Los Angeles, California; ⁵ University of Michigan Hospital, Ann Arbor, Michigan; ⁶ University of Virginia Health Science Center, Charlottesville, Virginia; ⁷ M. D. Anderson Cancer Center, Houston, Texas; ⁸ University of Texas Southwestern Medical Center, Dallas, Texas; ⁹ University of Wisconsin Hospital, Madison, Wisconsin; ¹⁰ Memorial Sloan-Kettering Cancer Center, New York, New York; ¹¹ Northwestern University, Chicago, Illinois; and ¹² Cancer Therapy Evaluation Program, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: John G. Kuhn, Pharmacotherapy Education and Research Center, University of Texas Health Science Center, 7703 Floyd Curl Drive, MSC 6220, San Antonio, TX 78229-3900. Phone: 210-567-8355; Fax: 210-567-8328; E-mail: Kuhn{at}uthscsa.edu.

Purpose: To characterize the pharmacokinetics of temsirolimus and its major metabolite, sirolimus, in patients receiving enzyme-inducing antiepileptic drugs (EIAED) compared with patients receiving non-EIAEDs. An additional objective was to determine whether concentrations of temsirolimus or sirolimus were achieved in brain tumor tissue.

Experimental Design: Patients with recurrent malignant gliomas not receiving EIAEDs initially received temsirolimus weekly at a dose of 250 mg i.v. The dose was subsequently reduced to 170 mg due to intolerable side effects. For patients taking EIAEDs, the starting dose of temsirolimus was 250 mg with standard dose escalation until the maximal tolerated dose was established. Ten whole blood samples were obtained over a period of 24 h after administration of temsirolimus for pharmacokinetic assessments. Patients eligible for cytoreductive surgery received temsirolimus before tumor resection. Whole blood and tumor tissue were obtained for analysis.

Results: Significant differences in the pharmacokinetic variables for temsirolimus and sirolimus were observed between the two patient groups at a comparable dose level of 250 mg. For patients receiving EIAEDs, the systemic exposure to temsirolimus was lower by 1.5-fold. Likewise, peak concentrations and exposure to sirolimus were lower by 2-fold. Measurable concentrations of temsirolimus and sirolimus were observed in brain tumor specimens. The average tissue to whole blood ratio for temsirolimus was 1.43 and 0.84 for sirolimus.

Conclusions: Drugs that induce cytochrome P450 3A4, such as EIAEDs, significantly affect the pharmacokinetics of temsirolimus and its active metabolite, sirolimus. Total exposure to temsirolimus and sirolimus was lower in the EIAED group at the maximum tolerated dose of 250 mg compared with the non-EIAED group at the maximum tolerated dose of 170 mg. However, brain tumor tissue concentrations of temsirolimus and sirolimus were relatively comparable in both groups of patients at their respective dose levels. Correlative analyses of the tissue for the inhibition of the key regulators (p70^S6 kinase and 4E-binding protein 1) of mammalian target of rapamycin are necessary to define the therapeutic significance of the altered exposure to temsirolimus.

This article has been cited by other articles:

				B. Shor, W.-G. Zhang, L. Toral-Barza, J. Lucas, R. T. Abraham, J. J. Gibbons, and K. Yu A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis Cancer Res., April 15, 2008; 68(8): 2934 - 2943. [Abstract] [Full Text] [PDF]